Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Generative Artificial Intelligence (AI) In Pharmaceutical Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The generative artificial intelligence (AI) in pharmaceutical market size has experienced significant expansion in recent years. This market is anticipated to expand from $2.43 billion in 2025 to $3.19 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 31.2%. The growth observed in the past can be linked to factors such as increasing r&d investments in pharmaceuticals, a rise in chronic diseases, the growing adoption of AI in early-stage drug discovery, the expansion of the biologics market, and the availability of large-scale molecular datasets.
The generative artificial intelligence (AI) in pharmaceutical market is set to experience rapid expansion in the coming years, with its valuation projected to reach $9.36 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 30.9%. This significant growth anticipated for the forecast period can be primarily attributed to ongoing advancements in generative AI algorithms, the proliferation of precision medicine, the increasing adoption of virtual clinical trials, a rising demand for biologics optimization, and the integration of AI with cloud computing solutions. Key developments expected to shape this period include AI-driven drug design optimization, predictive molecular modeling, virtual screening of compound libraries, the progression of personalized medicine, and biopharmaceutical efficacy simulation.
Download A Free Sample Report For Comprehensive Market Insights:
Generative Artificial Intelligence (AI) In Pharmaceutical Market Demand Drivers: What Is Fueling Industry Growth?
A growing emphasis on personalized medicine is anticipated to fuel the expansion of generative artificial intelligence (AI) within the pharmaceutical market moving ahead. This approach customizes medical care for individual patients by considering their unique characteristics, requirements, and preferences, drawing upon genetic, environmental, and lifestyle data. The rising attention to personalized medicine stems from progress in genetic research and technology, which allows for the creation of more accurate and effective treatments specifically designed for each patient. In pharmaceuticals, personalized medicine utilizes generative AI to create customized drug therapies, leading to better treatment effectiveness and improved patient results. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, a significant increase from six in 2022. Consequently, the heightened focus on personalized medicine is a key factor propelling the advancement of generative artificial intelligence (AI) in the pharmaceutical market.
Generative Artificial Intelligence (AI) In Pharmaceutical Market Segment Analysis Highlighting Growth Areas
The generative artificial intelligence (AI) in pharmaceutical market covered in this report is segmented –
1) By Type: Small Molecule, Large Molecule
2) By Technology: Deep Learning, Natural Language Processing, Querying Method, Context-Aware Processing, Other Technologies
3) By Application: Clinical Trial Research, Drug Discovery, Research And Development, Other Applications
Subsegments:
1) By Small Molecule: Drug Discovery And Design, Lead Optimization For Small Molecule Compounds, Predictive Modeling For Pharmacokinetics And Toxicity, Virtual Screening Of Compound Libraries, Personalized Medicine Approaches For Small Molecule Therapies
2) By Large Molecule: Biologics Discovery And Development, Monoclonal Antibody Design, Protein Engineering And Optimization, Vaccine Development And Optimization, Predictive Models For Biopharmaceutical Efficacy And Safety.
#Generative Artificial Intelligence (AI) In Pharmaceutical Market Growth Trends: What Is Influencing The Future Outlook?
Leading companies operating in generative artificial intelligence (AI) in the pharmaceutical market are developing new offerings, such as AI healthcare microservices, to optimize drug discovery processes. These AI healthcare microservices are modular, cloud-based solutions that leverage artificial intelligence to improve healthcare functions, including drug discovery, medical imaging, and diagnostics. For instance, in March 2024, Nvidia Corporation, a US-based technology company, launched generative AI microservices. This introduction features optimized NIM AI models and workflows with APIs for building cloud-native applications. It provides advanced imaging, natural language, and speech recognition, along with digital biology capabilities. The essential tools, including Parabricks, MONAI, NeMo, Riva, and Metropolis, are accessible as CUDA-X microservices, thereby enhancing workflows in drug discovery and genomics.
Generative Artificial Intelligence (AI) In Pharmaceutical Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the generative artificial intelligence (AI) in pharmaceutical market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Fujitsu Limited, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., NVIDIA Corporation, Conduent Incorporated, XtalPi Inc., Insilico Medicine Inc., Numerate Inc., Atomwise Inc., BenevolentAI Limited
Access The Complete Generative Artificial Intelligence (AI) In Pharmaceutical Market Report:
Generative Artificial Intelligence (AI) In Pharmaceutical Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the generative artificial intelligence (AI) in the pharmaceutical market in 2025. The regions covered in the generative artificial intelligence (AI) in pharmaceutical market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.